[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600854":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":11,"centralContacts":44,"locations":50,"responsibleParty":88,"collaborators":11,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":11,"eligibilityCriteria":96,"healthyVolunteers":92,"sex":97,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":11,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":11,"overallStatus":53,"whyStopped":11,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group A","EXPERIMENTAL",null,[13,14],"Drug: SHR2554 Tablets","Drug: SHR-A1811 Injection",{"label":16,"type":10,"description":11,"interventionNames":17},"Treatment group B",[13,18],"Drug: SHR-A1904 Injection",{"label":20,"type":10,"description":11,"interventionNames":21},"Treatment group C",[13,22],"Drug: SHR-1701 Injection",{"label":24,"type":10,"description":11,"interventionNames":25},"Treatment group D",[13],[27,32,36,40],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","SHR2554 Tablets","Oral SHR2554 tablets.",[9,16,20,24],{"type":28,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"SHR-A1811 Injection","SHR-A1811 for injection.",[9],{"type":28,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"SHR-A1904 Injection","SHR-A1904 for injection.",[16],{"type":28,"name":41,"description":42,"armGroupLabels":43,"otherNames":11},"SHR-1701 Injection","SHR-1701 injection",[20],[45],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Botao Zhu","CONTACT","+86-021-23511999","botao.zhu.bz19@hengrui.com",[51,72],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Harbin Medical University Cancer Hospital","RECRUITING","Harbin","Heilongjiang","150081","China","CN",{"type":60,"coordinates":61},"Point",[62,63],126.65,45.75,{"lat":63,"lon":62},[66,70],{"name":67,"role":47,"phone":68,"phoneExt":11,"email":69},"Yanqiao Zhang","+86-13845120210","yanqiaozhanggcp@163.com",{"name":67,"role":71,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":73,"status":53,"city":74,"state":75,"zip":76,"country":57,"countryCode":58,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","450052",{"type":60,"coordinates":78},[79,80],113.64861,34.75778,{"lat":80,"lon":79},[83,87],{"name":84,"role":47,"phone":85,"phoneExt":11,"email":86},"Feng Wang","+86-13938244776","fengw010@163.com",{"name":84,"role":71,"phone":11,"phoneExt":11,"email":11},{"type":89,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100600854","phase-2-safety-and-efficacy-of-shr2554-combined-with-other-antitumor-therapies-in-gastric-or-gastro-oesophageal-junction-adenocarcinoma-100600854",false,"NCT07102901","Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","A Multicenter, Open-Label Phase II Clinical Study Evaluating the Safety, Tolerability and Efficacy of SHR2554 Tablets in Combination With Other Antitumor Therapies in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. At least 18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.\n2. Has at least 1 measurable lesion based on investigator imaging assessment (computed tomography or magnetic resonance imaging) using RECIST v1.1 at screening.\n3. Is willing to provide an adequate tumor sample.\n4. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at Screening.\n\nExclusion Criteria:\n\n1. Presence of dysphagia or other factors impairing oral administration of SHR2554.\n2. Has previously been treated with any enhancer of zeste homolog inhibitors.\n3. Uncontrolled or significant cardiovascular disease.\n4. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.\n5. Has active autoimmune diseases requiring systemic corticosteroids\u002Fimmunosuppressants.\n6. History of known hypersensitivity to SHR2554 or excipients.\n7. Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection requiring treatment with intravenous (IV) antibiotics, antivirals, or antifungals.\n8. Diagnosis of other malignancies within 5 years prior to the first dose of investigational product.\n9. Has history of interstitial lung disease (ILD), non-infectious pneumonitis requiring systemic glucocorticoids, current suspected\u002Fconfirmed ILD, or clinically significant pulmonary disease history.\n10. Psychological, social, familial, or geographical factors that would prevent regular follow-up.","ALL","18 Years","75 Years",{"count":101,"type":102},351,"ESTIMATED","INTERVENTIONAL",[105],"PHASE2","This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.",[108,109,110],"Advanced Gastric Cancer","Metastatic Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","2025-09-09",{"date":113,"type":114},"2025-09-10","ACTUAL",{"date":116,"type":114},"2025-09-05",{"date":118,"type":102},"2027-12",{"name":5,"class":6},2]